Tertiary peritonitis due to Candida famata: Infection by an atypical yeast
DOI:
https://doi.org/10.51481/amc.v59i1.952Keywords:
Non-albicans Candida species, Candida famata peritonitis, Tertiary fungal peritonitisAbstract
Candida famata is a halotoleran, vitamin B2 overproducing yeast that is rarely associated with infections in humans, but is commonly utilized in industrial processes. In our service, it had been detected only once before in a patient with mediastinitis. The outcome of that infection was fatal. Not only were we unfamiliar with the management of infection by this agent, but after performing a thorough literary review, we were unable to find published reports of infections by this pathogen as the cause of tertiary peritonitis. We report the case of a 37 year old male who after suffering a stab wound to his abdomen and having multiple complications associated with this event, developed tertiary peritonitis by C. famata, that was treated with casponfungin and an open abdomen utilizing negative pressure wound therapy with instillation which yielded a satisfactory response to the therapy. This report may be of use in the event that clinicians are confronted with this condition in the future.
Downloads
References
Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538-1548.
Weiss G, Meyer F, Lippert H. Infectiological diagnostic problems in tertiary peritonitis. Langenbeck's Arch Surg. 2006;391:473-482.
Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: Clinical features of a complex nosocomial infection. World J Surg. 1998;22:158-163.
Mishra SP, Tiwary SK, Mishra M, Gupta SK. An introduction of Tertiary Peritonitis. J Emerg Trauma Shock. 2014;7:121-123.
Panhofer P, Izay B, Riedl M, Ferenc V, Ploder M, Jakesz R, et al. Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitis. Langenbeck's Arch Surg. 2009;394:265-271.
Dmytruk K V., Sibirny AA. Candida famata (Candida flareri). Yeast. 2012;29:453-458.
Seiler H, Busse M. The yeasts of cheese brines. Int J Food Microbiol. 1990;11:289-303.
Saldanha-Da-Gama A, Malfeito-Ferreira M, Loureiro V. Characterization of yeasts associated with Portuguese pork-based products. Int J Food Microbiol. 1997;37:201-207.
Linardi VR, Dias JC, Rosa CA. Utilization of acetonitrile and other aliphatic nitriles by a Candida famata strain. FEMS microbiology letters. 1996; 144:6771.
Dmytruk K, Lyzak O, Yatsyshyn V, Kluz M, Sibirny V, Puchalski C, et al. Construction and fed-batch cultivation of Candida famata with enhanced riboflavin production. J Biotechnol. 2014;172:11-7.
Adler LE, Blomberg AN, Nilsson AN. Glycerol metabolism and osmoregulation in the salt-tolerant yeast Debaryomyces hansenii. J bacteriology. 1985;162:300306.
Nishikawa A, Sugita T, Shinoda T. Differentiation between Debaryomyces hansenii/Candida famata complex and Candida guilliermondii by polymerase chain reaction. EMS Immunology &F Medical Microbiology. 1997;19:125-9.
Martos PG, de Sola FG, Marín P, García-Agudo L, García-Agudo R, Tejuca F, Calle L. Fungal peritonitis in continuous ambulatory peritoneal dialysis: a 10 cases description. Nefrologia. 2009;29:534-539.
Wagner D, Sander A, Bertz H, Finke J, Kern W V. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection. 2005;33:397-400.
Luis J, Benavides I, Rodríguez DS, Menchaca RT, González G, González EG, et al. Especies de Candida no albicans en la consulta de ginecologia. Med Univ. 2007;9:161-165.
Manzano-Gayosso P, Méndez-Tovar LJ, Arenas R, Hernández-Hernández F, Millán-Chiu B, Torres-Rodríguez JM, et al. Levaduras causantes de onicomicosis en cuatro centros dermatológicos mexicanos y su sensibilidad antifúngica a compuestos azólicos. Rev Iberoam Micol. 2011;28:32-35.
León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, AlvarezLerma F, et al. A bedside scoring system for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730-737.
Sanchez Betancourt AA, Sibaja Alvarez P, Camacho RA, Guevara Espinoza E. Candida famata mediastinitis. A rare complication of open heart surgery. Case report and brief review. IDCases. Elsevier; 2016;5:37-39.
Beyda ND, Chuang SH, Jahangir Alam M, Shah DN, Ng TM, McCaskey L, et al. Treatment of Candida famata bloodstream infections: Case series and review of the literature. J Antimicrob Chemother. 2013;68:438-443.
Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003;41:78-83.
Zuluaga Rodríguez A, de Bedout Gomez C, Agudelo Restrepo CA, Hurtado Parra H, Arango Arteaga M, Restrepo Moreno Angela, et al. Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellin, Colombia (2001-2007). Rev Iberoam Micol. 2010;27:125-129.
Downloads
Published
Versions
- 2017-02-02 (3)
- 2020-07-19 (2)
- 2017-02-02 (1)
Issue
Section
License
Copyright (c) 2017 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
